Cargando…

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer

Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, makin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Caixia, Ye, Wenlei, Zhou, Wenni, Ye, Zhikang, Yang, Weihong, Cheng, Zhongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791028/
https://www.ncbi.nlm.nih.gov/pubmed/36578942
http://dx.doi.org/10.3389/fonc.2022.1010158
_version_ 1784859308704399360
author Li, Caixia
Ye, Wenlei
Zhou, Wenni
Ye, Zhikang
Yang, Weihong
Cheng, Zhongping
author_facet Li, Caixia
Ye, Wenlei
Zhou, Wenni
Ye, Zhikang
Yang, Weihong
Cheng, Zhongping
author_sort Li, Caixia
collection PubMed
description Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, making it impossible to launch large-scale prospective studies and formulate the standard intervention for patients. We herein report a rare case of STO with liver primary cancer metastasis to the ovary and omentum in a 66-year-old woman. The patient underwent debulking surgery with the removal of the uterus, bilateral fallopian tubes, bilateral ovaries, appendix, and a large part of the omentum majus. Next-generation sequencing was conducted after the operation, identifying BRCA2 mutation. Because strongly refusing chemotherapy, she received olaparib as an experimental therapy. After the administration of surgery and olaparib, the serum value of cancer antigen 125 (CA125) and alpha fetoprotein (AFP) decreased dramatically and basically remained within the normal range. So far, she has achieved nearly 2-year survival and lives a relatively normal life with good quality.
format Online
Article
Text
id pubmed-9791028
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97910282022-12-27 Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer Li, Caixia Ye, Wenlei Zhou, Wenni Ye, Zhikang Yang, Weihong Cheng, Zhongping Front Oncol Oncology Secondary ovarian tumor [secondary tumor of the ovary (STO)] is not a frequent disease. To date, there is still a lack of standard treatment for STO due to the relative heterogeneity. Liver cancer metastasis to the ovary is extremely rare, with only 17 living cases having been reported so far, making it impossible to launch large-scale prospective studies and formulate the standard intervention for patients. We herein report a rare case of STO with liver primary cancer metastasis to the ovary and omentum in a 66-year-old woman. The patient underwent debulking surgery with the removal of the uterus, bilateral fallopian tubes, bilateral ovaries, appendix, and a large part of the omentum majus. Next-generation sequencing was conducted after the operation, identifying BRCA2 mutation. Because strongly refusing chemotherapy, she received olaparib as an experimental therapy. After the administration of surgery and olaparib, the serum value of cancer antigen 125 (CA125) and alpha fetoprotein (AFP) decreased dramatically and basically remained within the normal range. So far, she has achieved nearly 2-year survival and lives a relatively normal life with good quality. Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9791028/ /pubmed/36578942 http://dx.doi.org/10.3389/fonc.2022.1010158 Text en Copyright © 2022 Li, Ye, Zhou, Ye, Yang and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Caixia
Ye, Wenlei
Zhou, Wenni
Ye, Zhikang
Yang, Weihong
Cheng, Zhongping
Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title_full Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title_fullStr Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title_full_unstemmed Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title_short Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
title_sort case report: olaparib as an experimental therapy in a brca2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791028/
https://www.ncbi.nlm.nih.gov/pubmed/36578942
http://dx.doi.org/10.3389/fonc.2022.1010158
work_keys_str_mv AT licaixia casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer
AT yewenlei casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer
AT zhouwenni casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer
AT yezhikang casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer
AT yangweihong casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer
AT chengzhongping casereportolaparibasanexperimentaltherapyinabrca2mutatedpatientwithmetastaticovarianadenocarcinomathatoriginatedfromlivercancer